Sulphonylureas: Do we need to introspect safety again?

2^nd World Congress on Biomarkers & Clinical Research

12-14 September 2011 Baltimore, USA

Devindra Sehra, Sudhish Sehra and Shiv Tej Sehra

Scientific Tracks Abstracts: J Mol Biomark Diagn

Abstract :

Introduction: Sulphonylureas (SUs) are commonly prescribed medications for type 2 diabetes mellitus (T2DM) worldwide. Diff erences among SUs for kinetic and adenosine triphosphate sensitive potassium (KATP) channels selectivity and consequential extra pancreatic eff ects, though recognized in literature, are not considered by treatment guidelines. Areas Covered: Th e role of SUs in various systems related adverse eff ects have not been well understood. Inconsistencies in literature and lack of clinical trials assessing the long-term eff ects of monotherapy or combination therapy with SUs add to the concern. Th is review provides insights in issues concerning safety of SUs based on literature published between 1980-2011. A comprehensive search was carried out on PubMed, Embase & Cochrane databases using search terms viz. sulphonylureas, sulphonylureas and KATP channels, sulphonylureas & cardiovascular eff ects, sulphonylureas side eff ects etc. Expert Opinion: SUs have been linked to CV events, growth hormone (GH) disorder, malignancy, weight gain and CNS adverse eff ects. Th ese adverse eff ects generally get masked as they are thought to be related to diabetes per se. Th e current article will allow the fraternity to ponder and undertake further research on the ill eff ects of largely prescribed anti-diabetic medication.